Pharma giant Merck reported a 12.4% dip in earnings for the second quarter due to a 28% increase in research and development costs, as well as a 10% rise in materials and production costs, despite a 24% dip in income taxes. The top and bottom line came in above analysts’ expectations. The top line was driven by an 89% jump in sales of the cancer drug Keytruda, and a 30% climb in sales of cervical cancer preventing therapy Gardasil.
Infographics of the company's results can be found at https://news.alphastreet.com/merck-posts-upbeat-q2-results/
Infographics of the company's results can be found at https://news.alphastreet.com/merck-posts-upbeat-q2-results/